Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle.
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
02 03 2020
02 03 2020
Historique:
pubmed:
11
2
2020
medline:
28
10
2020
entrez:
11
2
2020
Statut:
ppublish
Résumé
Chikungunya virus (CHIKV) is an emerging arbovirus, endemic in many parts of the world, that is spread by travelers and adapts to new mosquito vectors that live in temperate climates. CHIKV replicates in many host tissues and initially causes a self-limiting febrile illness similar to dengue. However, in 30%-40% of cases, CHIKV also causes long-term painful and debilitating muscle and joint pain, the pathogenesis of which remains unknown. In this issue of the JCI, Lentscher et al. engineered a skeletal muscle-restricted CHIKV to show that while musculoskeletal disease requires viral replication in affected muscle, muscular pathology is mediated by host immunological factors. These findings de-link viral replication and disease symptoms, illuminate the virus-host interplay in CHIKV symptomatology, and raise the possibility that immune modulation is a therapeutic option. The results also highlight possible solutions to existing vaccine barriers and provide insights that may apply to other viral diseases.
Identifiants
pubmed: 32039916
pii: 134746
doi: 10.1172/JCI134746
pmc: PMC7269576
doi:
pii:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1099-1101Commentaires et corrections
Type : CommentOn
Références
Nat Rev Rheumatol. 2012 May 08;8(7):420-9
pubmed: 22565316
Curr Opin Virol. 2016 Feb;16:143-150
pubmed: 26986235
Elife. 2015 Jun 30;4:e08347
pubmed: 26126267
Lancet. 2014 Dec 6;384(9959):2046-52
pubmed: 25132507
Nat Commun. 2014 Jun 16;5:4084
pubmed: 24933611
Cell. 2007 Jun 29;129(7):1401-14
pubmed: 17604727
J Clin Invest. 2017 Mar 1;127(3):737-749
pubmed: 28248203
Clin Infect Dis. 2011 Mar 1;52(5):e121-6
pubmed: 21242326
J Virol. 2012 Jun;86(11):6084-96
pubmed: 22457519
J Clin Invest. 2020 Mar 2;130(3):1466-1478
pubmed: 31794434
Vaccine. 1986 Sep;4(3):157-62
pubmed: 3020820
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006919
pubmed: 30653504
Lancet Infect Dis. 2015 May;15(5):519-27
pubmed: 25739878
Lancet. 2007 Dec 1;370(9602):1840-6
pubmed: 18061059
Am J Trop Med Hyg. 2000 Jun;62(6):681-5
pubmed: 11304054
BMC Med. 2015 Apr 30;13:102
pubmed: 25976325
Cell. 2002 Sep 6;110(5):563-74
pubmed: 12230974
Emerg Infect Dis. 2011 May;17(5):910-3
pubmed: 21529410
Drugs. 2017 Nov;77(17):1865-1879
pubmed: 29094311
PLoS Negl Trop Dis. 2015 Sep 04;9(9):e0004007
pubmed: 26340754
mBio. 2018 Mar 6;9(2):
pubmed: 29511072
Vaccine. 2012 Oct 19;30(47):6713-20
pubmed: 22940380
Nat Med. 2010 Mar;16(3):334-8
pubmed: 20111039
Nat Med. 2017 Feb;23(2):192-199
pubmed: 27991917
J Infect Dis. 2014 Jun 15;209(12):1891-9
pubmed: 24403555